CTMX

CytomX Therapeutics, Inc. - Common Stock (CTMX)

About CytomX Therapeutics, Inc. - Common Stock (CTMX)

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies to address unmet need in oncology. The firm focuses on the field of antibody masking technologies through the development of its Probody therapeutic platform. The company was founded by Frederick W. Gluck, Nancy E. Stagliano, and Patrick S. Daugherty in February 2008 and is headquartered in South San Francisco, CA.

Details

Daily high

$2.83

Daily low

$2.74

Price at open

$2.80

52 Week High

$8.21

52 Week Low

$1.98

Market cap

601.4M

Dividend yield

Volume

20,094

Avg. volume

4.2M

P/E ratio

-6.04

CytomX Therapeutics, Inc. - Common Stock News